Lean European Open Survey on SARS-CoV-2 infected patients (COVID-19)

Lean European Open Survey on SARS-CoV-2 infected patients (COVID-19) - LEOSS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00021145

Enrollment

20000

Registered

2020-04-08

Start date

2020-03-16

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1

Interventions

Group 1: Patients with confirmed SARS-CoV-2 infection by PCR diagnosis from nasopharynx, oropharynx, bronchoalveaolar lavage, stool, or blood. Rapid tests are an acceptable alternative. Within the fra

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with confirmed SARS-CoV-2 infection by PCR diagnosis from nasopharynx, oropharynx, bronchoalveolar lavage, stool, or blood. Rapid tests are an acceptable alternative.

Exclusion criteria

Exclusion criteria: Confirmed SARS-CoV-2 infection without basic medical information including an initial blood sample and/or without any follow-up data.

Design outcomes

Primary

Measure	Time frame
To identify independent predictors of outcome in patients with diagnosed infection by SARS-CoV-2.	—

Secondary

Measure	Time frame
1) To assess the incidence of complicated and critical infection by SARS-CoV-2 2) To assess potential risk factors of complicated and critical infection by SARS-CoV-2 3) To assess clinical and sociodemographic characteristics of patients with SARS-CoV-2 infection (descriptive) 4) Assessment of the temporal relationship between the severity of SARS-CoV-2 infection and death 5) Assessment of regional differences in management and clinical outcome (descriptive) 6) Monitoring different trends over time (symptoms, incidence) (descriptive) 7) Estimation of direct health care costs based on length of stay, time on ICU, time with mechanical ventilation, time on ECMO (descriptive) 8) Cost utilization based on coded DRG and reimbursement (descriptive) 9) Assessment of the relationship between SARS-CoV-2 and the health economic burden in terms of direct treatment costs incurred during hospitalization (descriptive) 10) To describe the clinical pattern of disease: Sequence and reversibility of symptoms (descriptive), sequence of radiographic imaging findings (descriptive), sequence of laboratory lab results and patterns of disease severity (descriptive, multivariable binary logistic regression model), sequence of virus detection and quantity in various bodily fluids and samples (descriptive), immunological / inflammatory features of severe infection (descriptive, multivariable binary logistic regression model)	—

Measure

Time frame

1) To assess the incidence of complicated and critical infection by SARS-CoV-2 2) To assess potential risk factors of complicated and critical infection by SARS-CoV-2 3) To assess clinical and sociodemographic characteristics of patients with SARS-CoV-2 infection (descriptive) 4) Assessment of the temporal relationship between the severity of SARS-CoV-2 infection and death 5) Assessment of regional differences in management and clinical outcome (descriptive) 6) Monitoring different trends over time (symptoms, incidence) (descriptive) 7) Estimation of direct health care costs based on length of stay, time on ICU, time with mechanical ventilation, time on ECMO (descriptive) 8) Cost utilization based on coded DRG and reimbursement (descriptive) 9) Assessment of the relationship between SARS-CoV-2 and the health economic burden in terms of direct treatment costs incurred during hospitalization (descriptive) 10) To describe the clinical pattern of disease: Sequence and reversibility of symptoms (descriptive), sequence of radiographic imaging findings (descriptive), sequence of laboratory lab results and patterns of disease severity (descriptive, multivariable binary logistic regression model), sequence of virus detection and quantity in various bodily fluids and samples (descriptive), immunological / inflammatory features of severe infection (descriptive, multivariable binary logistic regression model)

—

Countries

Austria, Belgium, Bosnia & Herzegovina, Germany, Italy, Latvia, Spain, Switzerland, Turkey, United Kingdom

Contacts

Public ContactJörg Janne Vehreschild

University Hospital of Cologne, Faculty of Medicine and University Hospital Cologne, Department I for Internal Medicine, Cologne, Germany

janne.vehreschild@uk-koeln.de+49 221 478-88794

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026